Summarize the article with AI
Does Retatrutide Help Sleep Apnea? The Short Answer
In two Phase 3 trials, retatrutide reduced the severity of obstructive sleep apnea (OSA) more than placebo in adults with obesity or overweight. In TRIUMPH-1-OSA, in 243 people without diabetes, breathing interruptions during sleep fell by up to 34.3 per hour after 80 weeks, against 9.9 per hour on placebo. In TRIUMPH-2-OSA, in 448 people with type 2 diabetes, they fell by up to 25.4 per hour, against 10.3 on placebo. Both trials were published in the New England Journal of Medicine in October 2026.
Retatrutide is investigational and not approved for sleep apnea or any other use. Tirzepatide is the GLP-1-based medicine already approved for OSA in adults with obesity. The two have not been compared directly, and their trials differed.
How Sleep Apnea Was Studied
The two sleep apnea trials were nested within two larger 80-week Phase 3 trials: TRIUMPH-1, in adults with obesity or overweight without diabetes, and TRIUMPH-2, in adults with obesity or overweight and type 2 diabetes. Participants had a body-mass index of at least 27 and moderate to severe OSA, defined by an apnea–hypopnea index (AHI) of 15 or more, meaning at least 15 breathing pauses or partial pauses per hour of sleep. They were assigned to retatrutide 4 mg, 9 mg or 12 mg, or to placebo, once a week.
The primary end point was the change in AHI at week 80 with the 9 mg and 12 mg doses. At the start, the average AHI was 58.6 events per hour in TRIUMPH-1-OSA and 55.9 in TRIUMPH-2-OSA, and average body weight was 119.6 kg and 115.9 kg. The main results use a hybrid-treatment estimand, which counts results whether or not participants kept taking the drug, except after events suggesting the treatment had failed, where it estimates what would otherwise have happened; the investigators also report intention-to-treat results, which count everyone as randomized.
The Results
All three doses reduced AHI more than placebo in both trials. Counting everyone as randomized gave similar differences from placebo: 13.2, 24.7 and 22.5 events per hour on 4 mg, 9 mg and 12 mg in TRIUMPH-1-OSA, and 8.8, 13.9 and 15.0 in TRIUMPH-2-OSA.
Weight fell too. Over 80 weeks, participants on retatrutide lost 12.5% to 22.2% of their body weight in TRIUMPH-1-OSA and 12.1% to 18.5% in TRIUMPH-2-OSA, depending on the dose, against 4.8% and 5.6% on placebo. The most common adverse events were gastrointestinal. The published summary does not give rates of side effects or of stopping treatment for these two trials; the side effects reported across the larger trials are covered in retatrutide side effects.
Lilly's June 2026 announcement of the TRIUMPH-1 sleep apnea results used a third way of counting, the efficacy estimand, which assumes everyone stayed on treatment. On that basis it reported an AHI reduction of up to 36.1 events per hour, or 60.6%, from a baseline of 58.6. The figures describe the same trial counted in different ways.
Results in People With Type 2 Diabetes
TRIUMPH-2-OSA enrolled people with sleep apnea who also had type 2 diabetes. The reductions in AHI were smaller than in people without diabetes: 14.4 and 15.1 events per hour more than placebo on 9 mg and 12 mg, against 24.4 and 21.9 in TRIUMPH-1-OSA. Weight loss was also smaller, up to 18.5% against up to 22.2%. The two trials enrolled different people, so the difference between them is an observation, not a tested comparison.
How It Compares With Tirzepatide
The FDA approved tirzepatide on December 20, 2024, to treat moderate to severe OSA in adults with obesity; the FDA called it the first drug treatment option for certain patients with OSA. Its approval was based on two 52-week trials, SURMOUNT-OSA, in 469 adults without type 2 diabetes: one in people not using PAP therapy and one in people using it.
These figures cannot be lined up directly with retatrutide's. The tirzepatide trials lasted 52 weeks and were designed only for people with OSA; the retatrutide trials ran for 80 weeks within larger obesity trials; and the results were counted in different ways. Tirzepatide's sleep apnea trials also excluded people with type 2 diabetes, so there is no tirzepatide figure to set beside TRIUMPH-2-OSA. Claims that retatrutide "beats" tirzepatide for sleep apnea, or the reverse, are not supported by a head-to-head trial. How the two compare on weight loss is covered in retatrutide vs tirzepatide vs semaglutide.
Can Retatrutide Replace CPAP?
The trials do not answer that. TRIUMPH-1 included people with and without positive airway pressure (PAP) therapy, such as CPAP, but the published results do not show whether people could stop using it. Retatrutide is not approved, and no trial reported so far was designed to test it as a replacement for PAP therapy.
What Is Still Unknown
- How many people's OSA resolved or became mild on retatrutide; the published summary does not report it.
- Effects on symptoms such as daytime sleepiness.
- Whether the effect lasts after stopping treatment (see weight regain after stopping retatrutide).
- How retatrutide compares with tirzepatide in the same trial.
Lilly plans to submit retatrutide to the US Food and Drug Administration in the first quarter of 2027, and has said it has the data to seek approval for obstructive sleep apnea as well as obesity. What the FDA approves, if anything, will depend on its review.
Sources
- Grunstein RR, Somers VK, Azarbarzin A, et al. Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea. N Engl J Med. Published October 2026. DOI: 10.1056/NEJMoa2611477. (TRIUMPH-1-OSA and TRIUMPH-2-OSA)
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
- Eli Lilly. Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications. June 6, 2026.
- Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
- Eli Lilly. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. September 29, 2026. (TRIUMPH-2)
- U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. December 20, 2024.
- Eli Lilly. Announcement of the FDA approval of tirzepatide for moderate to severe obstructive sleep apnea in adults with obesity. December 20, 2024. (SURMOUNT-OSA results)
- Eli Lilly. US prescribing information for tirzepatide, section 14.2. Revised August 2026.
Medical Disclaimer: This article summarizes published trial results for general information only and is not medical advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and products sold online under its name are not sold or supplied by Lilly. Nothing here is a recommendation to start, stop or change any treatment, including PAP therapy.
Frequently asked questions
In two Phase 3 trials published in October 2026, retatrutide reduced breathing interruptions during sleep more than placebo after 80 weeks. In people without diabetes, they fell by up to 34.3 per hour, against 9.9 on placebo; in people with type 2 diabetes, by up to 25.4, against 10.3. Retatrutide is not approved for any use.
That has not been tested. Tirzepatide is approved for moderate to severe sleep apnea in adults with obesity, based on two 52-week trials that excluded people with type 2 diabetes. Retatrutide's trials ran for 80 weeks within larger obesity trials and were counted differently, so the numbers cannot be compared directly, and no head-to-head trial exists.
It is the developer's June 2026 figure for TRIUMPH-1: a reduction of up to 36.1 breathing interruptions per hour from a baseline of 58.6, calculated as if everyone stayed on treatment. The published paper reports the change in events per hour counted differently, 34.3 with 9 mg and 31.7 with 12 mg, against 9.9 on placebo.
The trials do not show that. TRIUMPH-1 included people with and without PAP therapy, but the published results do not report whether people could stop using it, and no trial so far was designed to test retatrutide as a replacement for PAP therapy.



